{"id":82237,"date":"2026-06-12T09:14:31","date_gmt":"2026-06-12T09:14:31","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/82237\/"},"modified":"2026-06-12T09:14:31","modified_gmt":"2026-06-12T09:14:31","slug":"ideaya-biosciences-idya-forms-clinical-partnership-with-roche-for-ide892-efficacy-study-4","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/82237\/","title":{"rendered":"Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study"},"content":{"rendered":"\n

IDEAYA Biosciences Inc. (NASDAQ:IDYA<\/a>) is one of the 10 best AI driven biotech stocks to invest in<\/a>.<\/p>\n

On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche\u2019s pan-RAS inhibitor, RG6505, in patients with MTAP-deleted pancreatic ductal adenocarcinoma, Ideaya Biosciences Inc. (NASDAQ:IDYA) and Roche (RHHBY) formed a clinical partnership. Roche will provide RG6505 for the investigation, and Ideaya will oversee and finance the combination experiment.<\/p>\n

\"\" <\/p>\n

Romaset\/Shutterstock.com<\/p>\n

Whether used separately or in combination, both firms will keep all commercial licenses to their individual treatments. Ideaya and Roche will share governance of the cooperation. Subject to both firms\u2019 approval, the agreement also allows for the evaluation of a three-drug combination that comprises IDE892, RG6505, and IDE397, Ideaya\u2019s Phase 2 MAT2A inhibitor.<\/p>\n

On June 1, IDEAYA Biosciences (NASDAQ:IDYA) shared its full Phase 2\/3 data for its skin cancer drug trial at the ASCO meeting. The global study evaluated 313 patients, and the big news is that their new drug combination cut the risk of the disease getting worse by 58%.<\/p>\n

Patients on the new treatment went 6.9 months without the disease progressing, compared to only 3.1 months for patients on standard treatments. The technical data also showed a major increase in response rates above 37% versus 5.8%, alongside a 73.3% disease control rate compared to 31.1% for the control group.<\/p>\n

The company is already working on its official FDA application under a real-time review program, and they expect to finish submitting everything in the second half of 2026. The drug was mostly safe, and very few people stopped taking it. Final survival data is not ready yet, but the early trends look promising.<\/p>\n

IDEAYA Biosciences Inc. (NASDAQ:IDYA) is a precision medicine oncology company, offering antibody drug inhibitors such as IDE161, IDE705, IDE397, IDE892, and more. The company also offers Darovasertib in multiple clinical trials and provides preclinical research programs focused on pharmacological inhibition. These include the INQUIRE chemical library and the HARMONY machine-learning engines.<\/p>\n

While we acknowledge the potential of IDYA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/a>.<\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and 15 Stocks That Will Make You Rich in 10 Years<\/a>.<\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in. On…\n","protected":false},"author":2,"featured_media":82238,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[42137,40100,42136,40113,134],"class_list":["post-82237","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-drug-combination","tag-ideaya-biosciences","tag-ideaya-biosciences-inc","tag-idya","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116736377968155828","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/82237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=82237"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/82237\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/82238"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=82237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=82237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=82237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}